Sample size calculations
We based the sample size calculations on the primary outcome change in CD8 count from T0 to T12. At the time of writing the trial protocol, we hypothesized that switching to DTG/3TC could be associated with a higher CD8 activation compared to switching to B/F/TAF. In particular, on the basis of data previously published in the literature available at the time of the protocol, we assumed that CD8 count could increase by 20 cells/mm